Linked Life Data

14990642

Source:http://linkedlifedata.com/resource/pubmed/id/14990642

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2004-3-1
pubmed:abstractText
To determine the efficacy and safety of EM-800 (SCH-57050), the precursor of acolbifene, a new, highly potent, orally active, pure antiestrogen in the mammary gland and endometrium, for the treatment of tamoxifen-resistant breast cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0732-183X
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
864-71
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed-meshheading:14990642-Administration, Oral, pubmed-meshheading:14990642-Adult, pubmed-meshheading:14990642-Aged, pubmed-meshheading:14990642-Aged, 80 and over, pubmed-meshheading:14990642-Benzopyrans, pubmed-meshheading:14990642-Biological Availability, pubmed-meshheading:14990642-Breast Neoplasms, pubmed-meshheading:14990642-Carcinoma, pubmed-meshheading:14990642-Dose-Response Relationship, Drug, pubmed-meshheading:14990642-Drug Administration Schedule, pubmed-meshheading:14990642-Drug Resistance, Neoplasm, pubmed-meshheading:14990642-Estrogen Antagonists, pubmed-meshheading:14990642-Female, pubmed-meshheading:14990642-Humans, pubmed-meshheading:14990642-Lymphatic Metastasis, pubmed-meshheading:14990642-Maximum Tolerated Dose, pubmed-meshheading:14990642-Middle Aged, pubmed-meshheading:14990642-Neoplasm Staging, pubmed-meshheading:14990642-Prodrugs, pubmed-meshheading:14990642-Propionates, pubmed-meshheading:14990642-Prospective Studies, pubmed-meshheading:14990642-Risk Assessment, pubmed-meshheading:14990642-Survival Analysis, pubmed-meshheading:14990642-Tamoxifen, pubmed-meshheading:14990642-Treatment Outcome
pubmed:year
2004
pubmed:articleTitle
Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer.
pubmed:affiliation
Oncology and Molecular Endocrinology Research Center, Laval University Medical Center, 2705 Laurier Blvd, T-3-67, Quebec City, Quebec, G1V 4G2, Canada. fernand.labrie@crchul.ulaval.ca
pubmed:publicationType
Journal Article, Clinical Trial, Multicenter Study, Clinical Trial, Phase II